Satellos Bioscience Inc (MSCLF)

$0.51 +0.01 (1.82%)
Market Cap 94.23M
Revenue (ttm) 0.00
Net Income (ttm) -20.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 89,300
Avg Vol 69,194
Day's Range N/A - N/A
Shares Out 185.09M
Stochastic %K 60%
Beta 1.08
Analysts Sell
Price Target $0.86

Company Profile

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an...

Industry: Biotechnology
Sector: Healthcare
Address:
Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
PennyScam
PennyScam Nov. 13 at 9:36 PM
$MSCLF Hello???! Get in there! Crazy K
1 · Reply
PennyScam
PennyScam Nov. 5 at 1:55 AM
$MSCLF Maybe do something like this.……https://www.osler.com/en/insights/updates/exchangeable-share-structures-an-overview/
0 · Reply
Florestan
Florestan Nov. 4 at 9:06 PM
$MSCLF https://musculardystrophynews.com/news/oral-therapy-moves-follow-strong-data-dmd-adults/
2 · Reply
PennyScam
PennyScam Nov. 4 at 3:54 PM
$MSCLF Can you guys merge with INVO or Naya Therapeutics already. Get it done. You guys are taking way too long. Cuckoo Penny
1 · Reply
Florestan
Florestan Nov. 1 at 2:11 AM
$MSCLF fellow watchers, are you a bull, or a bear? What's up? Too quiet for something so revolutionary.
1 · Reply
Florestan
Florestan Oct. 28 at 4:32 PM
$MSCLF seeing a number of new watchers here, introduce yourselves friends, don't stay too quiet 😎
0 · Reply
Florestan
Florestan Oct. 21 at 3:22 PM
$MSCLF - First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled - 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers - Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter - Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open the study in the U.S., subject to regulatory and clinical site approvals https://ir.satellos.com/news/news-details/2025/Satellos-Announces-First-Adult-Patient-Dosed-in-LT-001-an-Open-Label-Long-Term-Follow-Up-Study-of-SAT-3247-in-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
Florestan
Florestan Oct. 21 at 3:21 PM
$MSCLF - First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled - 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers - Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter - Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open the study in the U.S., subject to regulatory and clinical site approvals https://ir.satellos.com/news/news-details/2025/Satellos-Announces-First-Adult-Patient-Dosed-in-LT-001-an-Open-Label-Long-Term-Follow-Up-Study-of-SAT-3247-in-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
Florestan
Florestan Oct. 13 at 5:07 PM
$MSCLF https://www.biospace.com/press-releases/satellos-announces-new-data-further-demonstrating-safety-tolerability-and-functional-impact-of-sat-3247-in-first-in-human-trial-of-adults-with-duchenne-muscular-dystrophy
0 · Reply
theoptionsplug
theoptionsplug Oct. 10 at 6:58 AM
FRIDAY THINGS TO WATCH: 🏦9:45AM: Chicago Fed President Austan Goolsbee gives opening remarks and moderates a panel at the 19th Annual Community Bankers Symposium. 📈10:00AM: Economists watch the preliminary October University of Michigan survey for updates on consumer sentiment and inflation expectations. 📊2:00PM: September Monthly U.S. federal budget will be released 🎮 $EA launches Battlefield 6 on PS5, Xbox Series X|S, and PC with a global simultaneous release. Set in 2027, it depicts a conflict between a fractured NATO and the private military group Pax Armata. 🏀NBA preseason games in Macau’s Venetian Arena feature the Brooklyn Nets vs. Phoenix Suns, boosting The Venetian Macau owned by $SCHYY (a majority subsidiary of $LVS). 🧬 $CRSP, $DTIL, and $MSCLF present at the World Muscle Society Congress.
0 · Reply
Latest News on MSCLF
No data available.
PennyScam
PennyScam Nov. 13 at 9:36 PM
$MSCLF Hello???! Get in there! Crazy K
1 · Reply
PennyScam
PennyScam Nov. 5 at 1:55 AM
$MSCLF Maybe do something like this.……https://www.osler.com/en/insights/updates/exchangeable-share-structures-an-overview/
0 · Reply
Florestan
Florestan Nov. 4 at 9:06 PM
$MSCLF https://musculardystrophynews.com/news/oral-therapy-moves-follow-strong-data-dmd-adults/
2 · Reply
PennyScam
PennyScam Nov. 4 at 3:54 PM
$MSCLF Can you guys merge with INVO or Naya Therapeutics already. Get it done. You guys are taking way too long. Cuckoo Penny
1 · Reply
Florestan
Florestan Nov. 1 at 2:11 AM
$MSCLF fellow watchers, are you a bull, or a bear? What's up? Too quiet for something so revolutionary.
1 · Reply
Florestan
Florestan Oct. 28 at 4:32 PM
$MSCLF seeing a number of new watchers here, introduce yourselves friends, don't stay too quiet 😎
0 · Reply
Florestan
Florestan Oct. 21 at 3:22 PM
$MSCLF - First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled - 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers - Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter - Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open the study in the U.S., subject to regulatory and clinical site approvals https://ir.satellos.com/news/news-details/2025/Satellos-Announces-First-Adult-Patient-Dosed-in-LT-001-an-Open-Label-Long-Term-Follow-Up-Study-of-SAT-3247-in-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
Florestan
Florestan Oct. 21 at 3:21 PM
$MSCLF - First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled - 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers - Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter - Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open the study in the U.S., subject to regulatory and clinical site approvals https://ir.satellos.com/news/news-details/2025/Satellos-Announces-First-Adult-Patient-Dosed-in-LT-001-an-Open-Label-Long-Term-Follow-Up-Study-of-SAT-3247-in-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
Florestan
Florestan Oct. 13 at 5:07 PM
$MSCLF https://www.biospace.com/press-releases/satellos-announces-new-data-further-demonstrating-safety-tolerability-and-functional-impact-of-sat-3247-in-first-in-human-trial-of-adults-with-duchenne-muscular-dystrophy
0 · Reply
theoptionsplug
theoptionsplug Oct. 10 at 6:58 AM
FRIDAY THINGS TO WATCH: 🏦9:45AM: Chicago Fed President Austan Goolsbee gives opening remarks and moderates a panel at the 19th Annual Community Bankers Symposium. 📈10:00AM: Economists watch the preliminary October University of Michigan survey for updates on consumer sentiment and inflation expectations. 📊2:00PM: September Monthly U.S. federal budget will be released 🎮 $EA launches Battlefield 6 on PS5, Xbox Series X|S, and PC with a global simultaneous release. Set in 2027, it depicts a conflict between a fractured NATO and the private military group Pax Armata. 🏀NBA preseason games in Macau’s Venetian Arena feature the Brooklyn Nets vs. Phoenix Suns, boosting The Venetian Macau owned by $SCHYY (a majority subsidiary of $LVS). 🧬 $CRSP, $DTIL, and $MSCLF present at the World Muscle Society Congress.
0 · Reply
fullmetalll
fullmetalll Oct. 8 at 7:03 AM
$MSCLF who the watchers here? We wait
0 · Reply
Florestan
Florestan Oct. 7 at 2:34 PM
$MSCLF highly undervalued for real
0 · Reply
fullmetalll
fullmetalll Oct. 7 at 2:24 PM
$MSCLF Today 4% up
0 · Reply
fullmetalll
fullmetalll Oct. 7 at 2:20 PM
$MSCLF Slow, Volume 34.5K, lets go
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 9:07 PM
$MSCLF The thing here looks like it is completely undervalued. Hardly anyone knows the stock. How should it be known? How should sales come in here? Maybe they can be taken over. Let's go
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 8:15 PM
$MSCLF 116 watchers, what a Joke.
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 7:32 PM
$MSCLF What's this? Hardly any watchers, and Phase 2 is in. Surely there should be at least a 300% upside? There are no watchers. Very, very bullish.
1 · Reply
Florestan
Florestan Oct. 6 at 7:14 PM
$MSCLF waiting for our own $SPRB moment... https://ir.satellos.com/news/news-details/2025/Satellos-Announces-IND-Submission-to-the-U-S--FDA-and-Global-Regulatory-Filings-to-Advance-a-Phase-2-Clinical-Trial-of-SAT-3247-in-Children-with-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
himdiboss
himdiboss Oct. 3 at 3:28 PM
$MSCLF Okay 👀🚀
0 · Reply
Florestan
Florestan Sep. 29 at 7:04 PM
$MSCLF Game on.
0 · Reply
himdiboss
himdiboss Sep. 29 at 5:30 PM
$MSCLF Wow!! We’re almost to .52 whole cents again 😂😂😂💩
0 · Reply
HamBoneXoXo
HamBoneXoXo Sep. 23 at 5:25 AM
$MSCLF Their pill sounds quite interesting. Totally in a dmd class of its own and worth some investment. They likely got a reverse and raise upon entering nasdaq, so I wonder when is the good time to buy.
1 · Reply